Эрибулин в лечении антрациклин-таксан-резистентного рака молочной железы: большой шаг вперед на пути к решению проблемы

1. Jordan MA, Kamath K, Manna T et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005; 4: 1086–95.
2. Okouneva T, Azarenko O, Wilson L et al. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 2008; 7: 2003–11.
3. Smith J, Wilson L Azarenko O et al. Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability. Biochem 2010; 49 (6): 1331–7.
4. Funahishi Y, Okamoto K, Adachi Y et al. Eribulin mesylate reduces tumor micrienvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci 2014; 105: 1334–42.
5. Ozawa Y, Okamoto K, Adachi Y et al. Suppression of metastasis and improvement of drug distribution by eribulin mesylate. EORTC-NCI-AACR meeting, Barcelona, 2014; p. 030.
6. Agoulnik SI, Oestreicher JL, Taylor NH et al. Eribulin and paclitaxel differentially affect gene expression profiling of blood vessel cells and in vitro angiogenesis in cocultures of human endothelial cells with pericytes. Cancer Res 2013; 73 (Suppl. 8). Abstract 3830.
7. McCracken PJ, Ito K, Yanagimachi M et al. Eribulin alters vascular function in human triple-negative (TN) breast MX-1 and MDA-MB-231 tumor xenograft models as measured by DCE-MRI. Cancer Res 2013; 73 (Suppl. 8). Abstract 4502.
8. Matsui J, Toyama O, Ino M et al. Eribulin caused re-modeling of tumor vasculature altering gene expression profiling in angiogenesis and epithelial mesenchymal transition (EMT) signaling pathway of host cells within human breast cancer cell (BCC) xenografts in nude mice. Cancer Res 2013; 73 (Suppl. 8). Abstract 1413.
9. Yoshida T, Ozawa Y, Kimura T et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer 2014; 110: 1497–505.
10. Yoshida T, Kuznetsov G, Kimura T et al. Eribulin mesylate suppresses experimental metastasis in the MX-1 human breast cancer model by reversing phenotypic states between epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET). Mol Cancer Ther 2014; 12 (Suppl. 11): A296–A296. DOI:10.1158/1535-7163.TARG-13-A296.
11. Ueda Sh, Saeki T, Takeuchi H et al. In vivo omaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab. Br J Cancer 2016. DOI: 10.1038/ bjc.2016.122.
12. Goto W, Kashiwagi Sh, Kurata K et al. Clinical verification of antitumor autoimmune response in eribulin chemotherapy for breast cancer. AACR 2016. Abstract 5127.
13. Vahdat LT, Pruitt B, Fabian CJ et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. JCO 2009; 27 (18): 2954–61.
14. Cortes J, Vahdat L, Blum JL et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. JCO 2010; 28 (25): 3922–8.
15. Aogi K, Iwata H, Masuda N et al. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol 2012; 23 (6): 1441–8.
16. Brettschneider C, Lühmann D, Raspe H et al. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA). GMS Health Technol Assess 2011.
17. Gerber B, Freund M, Reimer T et al. Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. Dtsch Arztebl Int 2010; 107: 85–91.
18. Beslija S, Bonneterre J, Burstein HJ et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20 (11): 1771–85.
19. Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). 2007: May. http://www.fda.gov/downloads/ Drugs/Guidance Compliance RegulatoryInformation /Guidances/UCM071590.pdf
20. Ellis L, Bernstein D, Voest E et al. American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes. JCO 2014; 32: 1277–80.
21. Beusterien K, Grinspan J, Tencer T et al. Patient preference for chemotherapies used in breast cancer. Int J Womens Health 2012; 4: 279–87.
22. Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist 2008; 13 (Suppl. 2): 19–21.
23. Rugo H, O'Shaughnessy J, Perez E et al. Current treatment options for metastatic breast cancer: what now? Clin Adv Hematol Oncol 2011; 9 (Suppl. 25): 1–16. http://www.hematologyandoncology.net/files/ 2013/04/ho1111_sup251.pdf
24. Donoghue M, Lemery SJ, Yuan W et al. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a «physician's choice» control arm in a randomized approval trial. Clin Cancer Res 2012; 18: 1496–505.
25. Cortes J, O’Shaughnessy J et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a Phase 3 open-label randomised study. Lancet 2011; 377: 914–23.
26. Twelves C, Loesch D et al. Updated survival analysis of a Phase III study (EMBRACE) of eribulin mesylate versus treatment of physician’s choice in subjects with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. Presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), December 8–12, 2010; San Antonio, TX, USA. P6–14–18.
27. Blum JL, Twelves CJ, Dutcus C et al. Impact of the number of prior chemotherapy regimens on overall survival (OS) among subjects with locally recurrent or MBC treated with eribulin mesylate: results from the Phase III EMBRACE study. Presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), December 8–12, 2010; San Antonio, TX. USA. P6–13–01.
28. Twelves C, Akerele C et al. Eribulin mesylate (E7389) vs treatment of physician’s choice (TPC) in patiehts (pts) with metastatic breast cancer (MBC): subgroup analyses from the EMBRACE study. Ann Oncol 2010; 21 (Suppl. 8). Abstract 2750.
29. Kaufman PA, Awada A, Twelves Ch et al. Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. JCO 2015: 594–601; DOI: 10.1200/JCO.2013.52.4892.
30. Kaufman PA, Awada A et al. A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Presented at the 35th San Antonio Breast Cancer Symposium (SABCS), December 4–8, 2012; San Antonio, TX, USA. Presentation S6–6.
31. Kaufman PA, Cortes J et al. A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 – June 4, 2013; Chicago, IL, USA. Poster 1049.
32. Cortes J, Awada A et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a Phase III, open-label, randomized study. Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 – June 4, 2013; Chicago, IL, USA. Abstract 1050.
33. Cortes J, Hudgens S et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized a phase III trial. Breast Cancer Res Treat 2015. DOI: 10.1007/s10549-015-3633-7.
34. Velicova G, Hudgens S, Forsythe A et al. Health-related quality of life (HRQoL) and disease symptoms in patients with locally advanced or metastatic breast cancer (MBC) treated with eribulin or capecitabine in post anthracycline and taxane setting. ESMO 2014, poster 392Р.
35. Twelves Ch, Cortes J, Vahdat L et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat 2014. DOI: 10.1007/s10549-014-3144-y.
36. Pivot X, Marme F, Koenigsberg R et al. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol 2016. DOI: 10.1093/annonc/mdw203.
37. Faria C, Li X, Powers A et al. Effects of dose modification of eribulin mesylate in patients with locally recurrent or metastatic breast cancer. J Clin Oncol 2013; 13 (Suppl. 26). Abstract 157.
38. Muss H, Cortes J, Vahdat LT et al. Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer. Oncologist 2014; 19: 318–27.
39. Fabi A, Moscetti L, Ciccarese M et al. Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice. Future Oncology 2015; 11 (3): 431–8.
40. Манзюк Л.В., Коваленко Е.И., Артамонова Е.В. Эрибулин в лечении метастатического рака молочной железы. Вопр. онкологии. 2015; 2: 195–8. / Manziuk L.V., Kovalenko E.I., Artamonova E.V. Eribulin v lechenii metastaticheskogo raka molochnoi zhelezy. Vopr. onkologii. 2015; 2: 195–8. [in Russian]
41. Nishimura Sh, Takashima T, Kawajiri H et al. Clinival effects of prior chemotherapy on eribulin. ECC 20156. Abstract 1859.
42. Kish JK, Mougalian SS, Copher R et al. Utilization and outcomes of eribulin in triple negative metastatic breast cancer: real-world findings. SABCS 2016; p. 5–15–16.
43. Martin-Babau J, Robert M, Septans AL et al. Eribulin mesilat in metastatic breast cancer, a focus on a safety and efficacy in elderly patients. Results from the EVHALAVEN multicentric retrospective cohort. ECC 2015. Abstract 1320.
44. A comparison of toxicity and health care resource use between eribulin, capecitabine6 gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting. J Oncol Rharm Practice 2015; 21 (3): 170–7.
45. Kikuchi Y, Shirakawa K, Kanauchi H et al. A retrospective multicenter abservation study about comparative analysis on efficacy eribulin mesylate with taxane regimens. ECC 20156, poster P062.
46. Wilks Sh, Puhalla Sh, O’Shaughnessy J et al. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer. Clin Breast Cancer 2014; 14 (6): 405–12.
47. Araki K, Fukada I, Kobayashi K et al. Eribulin shoud be a candidate strategy in combination with pertuzumab plus trastuzumab for taxane pretreated HER2-positive advance breast cancer. SABCS 2016. P5–15–11.
48. Bischoff J, Barinoff J, Mundhenke C et al. A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with HER2-positive metastatic breast cancer (E-VITA). ESMO 2016. Abstract 2935.
49. Twelves C et al. Efficacy and safety of eribulin in combination with capecitabine in patients with metastatic breast cancer: an open-label, phase 2 dose-confirmation study. Presented at SABCS 2014. Abstract P3–13–04.
50. Kaklamani VG, Hugnes E, Siziopikou K et al. Phase II neoadjuvant clinical trial of carcoplatin and eribulin in women with triple negative early stage breast cancer (NCT01372579). ASCO 2015. Abstract 1017.
51. Hardy-Bessard A, Brocard F, Leheurteur M et al. ESMERALDA: Phase II trial evaluating the combination of eribulin (E) + bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): a GINECO group study. ESMO 2016. Abstract 3730.
52. Nanda R et al. J Clin Oncol 2016; 34: 2460–7.
53. Tolaney S, Savulsky C, Aktan G. Phase 1b/2 Study to Evaluate Eribulin Mesylate in Combination With Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer. SABCS 2016 [Abstr. P5–15–02].
54. Schoffski P, Maki R, Italiano A et al. Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). J Clin Oncol 2015; 33 (S): Abstr. LBA 10502.
55. Chawla S, Schoffski P et al. Subtype-specific activity in liposarcoma patients from a phase 3, open-label, randomized study of eribulin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. ASCO 2016; poster 163.
56. Gennari A, Conte PF, Rosso R et al. Survival of metastatic breast carcinoma patients over a 20-year period. A retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005; 104 (8): 1742–50.
57. Dawood SS et al. Is the proportion of patients with synchronous stage IV breast cancer surviving > 2 years increasing over time? ASCO 2013, abstr. 524. JCO 2013; 31 (15S): part I; p. 12s.
58. Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol 2010; 28: 1958–62.

________________________________________________

1. Jordan MA, Kamath K, Manna T et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005; 4: 1086–95.
2. Okouneva T, Azarenko O, Wilson L et al. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 2008; 7: 2003–11.
3. Smith J, Wilson L Azarenko O et al. Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability. Biochem 2010; 49 (6): 1331–7.
4. Funahishi Y, Okamoto K, Adachi Y et al. Eribulin mesylate reduces tumor micrienvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci 2014; 105: 1334–42.
5. Ozawa Y, Okamoto K, Adachi Y et al. Suppression of metastasis and improvement of drug distribution by eribulin mesylate. EORTC-NCI-AACR meeting, Barcelona, 2014; p. 030.
6. Agoulnik SI, Oestreicher JL, Taylor NH et al. Eribulin and paclitaxel differentially affect gene expression profiling of blood vessel cells and in vitro angiogenesis in cocultures of human endothelial cells with pericytes. Cancer Res 2013; 73 (Suppl. 8). Abstract 3830.
7. McCracken PJ, Ito K, Yanagimachi M et al. Eribulin alters vascular function in human triple-negative (TN) breast MX-1 and MDA-MB-231 tumor xenograft models as measured by DCE-MRI. Cancer Res 2013; 73 (Suppl. 8). Abstract 4502.
8. Matsui J, Toyama O, Ino M et al. Eribulin caused re-modeling of tumor vasculature altering gene expression profiling in angiogenesis and epithelial mesenchymal transition (EMT) signaling pathway of host cells within human breast cancer cell (BCC) xenografts in nude mice. Cancer Res 2013; 73 (Suppl. 8). Abstract 1413.
9. Yoshida T, Ozawa Y, Kimura T et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer 2014; 110: 1497–505.
10. Yoshida T, Kuznetsov G, Kimura T et al. Eribulin mesylate suppresses experimental metastasis in the MX-1 human breast cancer model by reversing phenotypic states between epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET). Mol Cancer Ther 2014; 12 (Suppl. 11): A296–A296. DOI:10.1158/1535-7163.TARG-13-A296.
11. Ueda Sh, Saeki T, Takeuchi H et al. In vivo omaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab. Br J Cancer 2016. DOI: 10.1038/ bjc.2016.122.
12. Goto W, Kashiwagi Sh, Kurata K et al. Clinical verification of antitumor autoimmune response in eribulin chemotherapy for breast cancer. AACR 2016. Abstract 5127.
13. Vahdat LT, Pruitt B, Fabian CJ et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. JCO 2009; 27 (18): 2954–61.
14. Cortes J, Vahdat L, Blum JL et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. JCO 2010; 28 (25): 3922–8.
15. Aogi K, Iwata H, Masuda N et al. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol 2012; 23 (6): 1441–8.
16. Brettschneider C, Lühmann D, Raspe H et al. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA). GMS Health Technol Assess 2011.
17. Gerber B, Freund M, Reimer T et al. Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. Dtsch Arztebl Int 2010; 107: 85–91.
18. Beslija S, Bonneterre J, Burstein HJ et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20 (11): 1771–85.
19. Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). 2007: May. http://www.fda.gov/downloads/ Drugs/Guidance Compliance RegulatoryInformation /Guidances/UCM071590.pdf
20. Ellis L, Bernstein D, Voest E et al. American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes. JCO 2014; 32: 1277–80.
21. Beusterien K, Grinspan J, Tencer T et al. Patient preference for chemotherapies used in breast cancer. Int J Womens Health 2012; 4: 279–87.
22. Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist 2008; 13 (Suppl. 2): 19–21.
23. Rugo H, O'Shaughnessy J, Perez E et al. Current treatment options for metastatic breast cancer: what now? Clin Adv Hematol Oncol 2011; 9 (Suppl. 25): 1–16. http://www.hematologyandoncology.net/files/ 2013/04/ho1111_sup251.pdf
24. Donoghue M, Lemery SJ, Yuan W et al. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a «physician's choice» control arm in a randomized approval trial. Clin Cancer Res 2012; 18: 1496–505.
25. Cortes J, O’Shaughnessy J et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a Phase 3 open-label randomised study. Lancet 2011; 377: 914–23.
26. Twelves C, Loesch D et al. Updated survival analysis of a Phase III study (EMBRACE) of eribulin mesylate versus treatment of physician’s choice in subjects with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. Presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), December 8–12, 2010; San Antonio, TX, USA. P6–14–18.
27. Blum JL, Twelves CJ, Dutcus C et al. Impact of the number of prior chemotherapy regimens on overall survival (OS) among subjects with locally recurrent or MBC treated with eribulin mesylate: results from the Phase III EMBRACE study. Presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), December 8–12, 2010; San Antonio, TX. USA. P6–13–01.
28. Twelves C, Akerele C et al. Eribulin mesylate (E7389) vs treatment of physician’s choice (TPC) in patiehts (pts) with metastatic breast cancer (MBC): subgroup analyses from the EMBRACE study. Ann Oncol 2010; 21 (Suppl. 8). Abstract 2750.
29. Kaufman PA, Awada A, Twelves Ch et al. Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. JCO 2015: 594–601; DOI: 10.1200/JCO.2013.52.4892.
30. Kaufman PA, Awada A et al. A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Presented at the 35th San Antonio Breast Cancer Symposium (SABCS), December 4–8, 2012; San Antonio, TX, USA. Presentation S6–6.
31. Kaufman PA, Cortes J et al. A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 – June 4, 2013; Chicago, IL, USA. Poster 1049.
32. Cortes J, Awada A et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a Phase III, open-label, randomized study. Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 – June 4, 2013; Chicago, IL, USA. Abstract 1050.
33. Cortes J, Hudgens S et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized a phase III trial. Breast Cancer Res Treat 2015. DOI: 10.1007/s10549-015-3633-7.
34. Velicova G, Hudgens S, Forsythe A et al. Health-related quality of life (HRQoL) and disease symptoms in patients with locally advanced or metastatic breast cancer (MBC) treated with eribulin or capecitabine in post anthracycline and taxane setting. ESMO 2014, poster 392Р.
35. Twelves Ch, Cortes J, Vahdat L et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat 2014. DOI: 10.1007/s10549-014-3144-y.
36. Pivot X, Marme F, Koenigsberg R et al. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol 2016. DOI: 10.1093/annonc/mdw203.
37. Faria C, Li X, Powers A et al. Effects of dose modification of eribulin mesylate in patients with locally recurrent or metastatic breast cancer. J Clin Oncol 2013; 13 (Suppl. 26). Abstract 157.
38. Muss H, Cortes J, Vahdat LT et al. Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer. Oncologist 2014; 19: 318–27.
39. Fabi A, Moscetti L, Ciccarese M et al. Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice. Future Oncology 2015; 11 (3): 431–8.
40. Manziuk L.V., Kovalenko E.I., Artamonova E.V. Eribulin v lechenii metastaticheskogo raka molochnoi zhelezy. Vopr. onkologii. 2015; 2: 195–8. [in Russian]
41. Nishimura Sh, Takashima T, Kawajiri H et al. Clinival effects of prior chemotherapy on eribulin. ECC 20156. Abstract 1859.
42. Kish JK, Mougalian SS, Copher R et al. Utilization and outcomes of eribulin in triple negative metastatic breast cancer: real-world findings. SABCS 2016; p. 5–15–16.
43. Martin-Babau J, Robert M, Septans AL et al. Eribulin mesilat in metastatic breast cancer, a focus on a safety and efficacy in elderly patients. Results from the EVHALAVEN multicentric retrospective cohort. ECC 2015. Abstract 1320.
44. A comparison of toxicity and health care resource use between eribulin, capecitabine6 gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting. J Oncol Rharm Practice 2015; 21 (3): 170–7.
45. Kikuchi Y, Shirakawa K, Kanauchi H et al. A retrospective multicenter abservation study about comparative analysis on efficacy eribulin mesylate with taxane regimens. ECC 20156, poster P062.
46. Wilks Sh, Puhalla Sh, O’Shaughnessy J et al. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer. Clin Breast Cancer 2014; 14 (6): 405–12.
47. Araki K, Fukada I, Kobayashi K et al. Eribulin shoud be a candidate strategy in combination with pertuzumab plus trastuzumab for taxane pretreated HER2-positive advance breast cancer. SABCS 2016. P5–15–11.
48. Bischoff J, Barinoff J, Mundhenke C et al. A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with HER2-positive metastatic breast cancer (E-VITA). ESMO 2016. Abstract 2935.
49. Twelves C et al. Efficacy and safety of eribulin in combination with capecitabine in patients with metastatic breast cancer: an open-label, phase 2 dose-confirmation study. Presented at SABCS 2014. Abstract P3–13–04.
50. Kaklamani VG, Hugnes E, Siziopikou K et al. Phase II neoadjuvant clinical trial of carcoplatin and eribulin in women with triple negative early stage breast cancer (NCT01372579). ASCO 2015. Abstract 1017.
51. Hardy-Bessard A, Brocard F, Leheurteur M et al. ESMERALDA: Phase II trial evaluating the combination of eribulin (E) + bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): a GINECO group study. ESMO 2016. Abstract 3730.
52. Nanda R et al. J Clin Oncol 2016; 34: 2460–7.
53. Tolaney S, Savulsky C, Aktan G. Phase 1b/2 Study to Evaluate Eribulin Mesylate in Combination With Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer. SABCS 2016 [Abstr. P5–15–02].
54. Schoffski P, Maki R, Italiano A et al. Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). J Clin Oncol 2015; 33 (S): Abstr. LBA 10502.
55. Chawla S, Schoffski P et al. Subtype-specific activity in liposarcoma patients from a phase 3, open-label, randomized study of eribulin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. ASCO 2016; poster 163.
56. Gennari A, Conte PF, Rosso R et al. Survival of metastatic breast carcinoma patients over a 20-year period. A retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005; 104 (8): 1742–50.
57. Dawood SS et al. Is the proportion of patients with synchronous stage IV breast cancer surviving > 2 years increasing over time? ASCO 2013, abstr. 524. JCO 2013; 31 (15S): part I; p. 12s.
58. Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol 2010; 28: 1958–62.

Е.В.Артамонова*

ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н.Блохина» Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23
*artamonovae@mail.ru

________________________________________________

E.V.Artamonova*

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
*artamonovae@mail.ru